These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 24284318)

  • 21. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.
    Yuste E; Sanford HB; Carmody J; Bixby J; Little S; Zwick MB; Greenough T; Burton DR; Richman DD; Desrosiers RC; Johnson WE
    J Virol; 2006 Mar; 80(6):3030-41. PubMed ID: 16501112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation.
    Poignard P; Fouts T; Naniche D; Moore JP; Sattentau QJ
    J Exp Med; 1996 Feb; 183(2):473-84. PubMed ID: 8627160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neutralization efficiency is greatly enhanced by bivalent binding of an antibody to epitopes in the V4 region and the membrane-proximal external region within one trimer of human immunodeficiency virus type 1 glycoproteins.
    Wang P; Yang X
    J Virol; 2010 Jul; 84(14):7114-23. PubMed ID: 20463081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.
    Gorny MK; Revesz K; Williams C; Volsky B; Louder MK; Anyangwe CA; Krachmarov C; Kayman SC; Pinter A; Nadas A; Nyambi PN; Mascola JR; Zolla-Pazner S
    J Virol; 2004 Mar; 78(5):2394-404. PubMed ID: 14963135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.
    Chakrabarti BK; Pancera M; Phogat S; O'Dell S; McKee K; Guenaga J; Robinson J; Mascola J; Wyatt RT
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):877-87. PubMed ID: 21158699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
    Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.
    Binley JM; Sanders RW; Clas B; Schuelke N; Master A; Guo Y; Kajumo F; Anselma DJ; Maddon PJ; Olson WC; Moore JP
    J Virol; 2000 Jan; 74(2):627-43. PubMed ID: 10623724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities.
    Alsmadi O; Tilley SA
    J Virol; 1998 Jan; 72(1):286-93. PubMed ID: 9420226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-1 ENVELOPE. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein.
    Chen J; Kovacs JM; Peng H; Rits-Volloch S; Lu J; Park D; Zablowsky E; Seaman MS; Chen B
    Science; 2015 Jul; 349(6244):191-5. PubMed ID: 26113642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.
    Andrabi R; Kumar R; Bala M; Nair A; Biswas A; Wig N; Kumar P; Pal R; Sinha S; Luthra K
    Virol J; 2012 Sep; 9():196. PubMed ID: 22971578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1.
    Nyambi PN; Gorny MK; Bastiani L; van der Groen G; Williams C; Zolla-Pazner S
    J Virol; 1998 Nov; 72(11):9384-91. PubMed ID: 9765494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
    Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR
    J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of amino acid changes in the human immunodeficiency virus type 1 transmembrane domain in antibody binding and neutralization.
    Lovelace E; Xu H; Blish CA; Strong R; Overbaugh J
    Virology; 2011 Dec; 421(2):235-44. PubMed ID: 22029936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies.
    Broder CC; Earl PL; Long D; Abedon ST; Moss B; Doms RW
    Proc Natl Acad Sci U S A; 1994 Nov; 91(24):11699-703. PubMed ID: 7972127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A virus binding assay for studying the antigenic landscape on intact, native, primary human immunodeficiency virus-type 1.
    Nyambi PN; Burda S; Bastiani L; Williams C
    J Immunol Methods; 2001 Jul; 253(1-2):253-62. PubMed ID: 11384686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10.
    Klein JS; Gnanapragasam PN; Galimidi RP; Foglesong CP; West AP; Bjorkman PJ
    Proc Natl Acad Sci U S A; 2009 May; 106(18):7385-90. PubMed ID: 19372381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discordant Antigenic Properties of Soluble and Virion SARS-CoV-2 Spike Proteins.
    Kumar S; Dasgupta S; Sajadi MM; Snyder GA; DeVico AL; Ray K
    Viruses; 2024 Mar; 16(3):. PubMed ID: 38543772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interactions of polyclonal and monoclonal anti-glycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV type 1 isolate: relationship to neutralization.
    Fouts TR; Trkola A; Fung MS; Moore JP
    AIDS Res Hum Retroviruses; 1998 May; 14(7):591-7. PubMed ID: 9591713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Purified complexes of HIV-1 envelope glycoproteins with CD4 and CCR5(CXCR4): production, characterization and immunogenicity.
    Xiao X; Phogat S; Shu Y; Phogat A; Chow YH; Wei OL; Goldstein H; Broder CC; Dimitrov DS
    Vaccine; 2003 Oct; 21(27-30):4275-84. PubMed ID: 14505910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.